Wednesday, June 10, 2026

Patent intelligence · EP

EP 3986378

PHARMAZEUTISCHE ZUSAMMENSETZUNGEN IN FORM VON GEL MIT XYLOGLUCAN UND ALKOHOLEN ZUR KONTROLLIERTEN FREISETZUNG VON WIRKSTOFFEN

granted A61K 9/ 00 A IA61K 9/ 06 A IA61K 38/ 21 A IA61K 47/ 10 A I
Status granted
Pipeline programs 6
Years to expiry 16
Applicant portfolio 25
Patent details — EP 3986378
Jurisdiction
EP
Status
granted
Grant date
Apr 27, 2022
Expiration
Apr 22, 2042
Applicant
ALFASIGMA SPA [IT]
CPC classes
A61K 9/ 00 A I, A61K 9/ 06 A I, A61K 38/ 21 A I, A61K 47/ 10 A I
View on Google Patents ↗

Quick answer

EP 3986378 (PHARMAZEUTISCHE ZUSAMMENSETZUNGEN IN FORM VON GEL MIT XYLOGLUCAN UND ALKOHOLEN ZUR KONTROLLIERTEN FREISETZUNG VON WIRKSTOFFEN) is held by ALFASIGMA SPA [IT]. Status: granted. Granted Apr 27, 2022. Expires Apr 22, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
ALFASIGMA SPA [IT]
Grant date
Expiration
Claims
CPC classes
A61K 9/ 00 A I, A61K 9/ 06 A I, A61K 38/ 21 A I, A61K 47/ 10 A I, A61K 47/ 36 A I, A61K/3821

More from ALFASIGMA SPA [IT]

Related pharmaceutical patents in our USPTO index.

  1. WO 2026027669

    BIOMARQUEURS POUR DÉTERMINER LE TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AVEC DU FILGOTINIB

    ALFASIGMA SPA [IT] · Expires Jan 31, 2046

    granted
  2. IT 202300014295

    COMPOSIZIONI ORODISPERSIBILI COMPRENDENTI BETAMETASONE FOSFATO

    ALFASIGMA SPA [IT] · Expires Jan 7, 2045

    granted
  3. IT 202300012522

    FLUOROMETIL-CARNITINA PER USO COME INIBITORE DI COLINA TRIMETILAMMINA (TMA) LIASI.

    ALFASIGMA SPA [IT] · Expires Dec 17, 2044

    granted
  4. AU 2023257308

    USES OF FARNESOID X RECEPTOR AGONISTS

    ALFASIGMA S P A [IT] · Expires Oct 5, 2044

    granted
  5. IT 202300006237

    COMPOSIZIONI NUTRACEUTICHE PER IL TRATTAMENTO O PREVENZIONE DI DISORDINI CONNESSI ALLA TRIMETILAMINURIA.

    ALFASIGMA SPA [IT] · Expires Oct 1, 2044

    granted
  6. IT 202300001434

    PRODOTTO DI FERMENTAZIONE PER USO NEL TRATTAMENTO DI PATOLOGIE ASSOCIATE ALLA SINDROME METABOLICA E STEATOSI EPATICA.

    ALFASIGMA SPA [IT] · Expires Jul 27, 2044

    granted
  7. CA 3263063

    VELUSETRAG DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA PSEUDO-OBSTRUCTION INTESTINALE CHRONIQUE (POIC)

    ALFASIGMA SPA [IT] · Expires Mar 23, 2044

    granted
  8. IT 202200013882

    PRODOTTO DI FERMENTAZIONE PER IL TRATTAMENTO DI MALATTIE INFIAMMATORIE.

    ALFASIGMA SPA [IT] · Expires Dec 30, 2043

    granted

Frequently asked questions

What is US patent 3986378?

EP 3986378 (PHARMAZEUTISCHE ZUSAMMENSETZUNGEN IN FORM VON GEL MIT XYLOGLUCAN UND ALKOHOLEN ZUR KONTROLLIERTEN FREISETZUNG VON WIRKSTOFFEN) is held by ALFASIGMA SPA [IT]. Status: granted. Granted Apr 27, 2022. Expires Apr 22, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns EP 3986378?

ALFASIGMA SPA [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does EP 3986378 expire?

Our index shows an expiration date of Apr 22, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.